Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids

Hepatology

Volumn 61, Issue 5, 2015, Pages 1565-1578

  Arendt, Bianca M ^a   Comelli, Elena M ^b   Ma, David W L ^c   Lou, Wendy ^b   Teterina, Anastasia ^a   Kim, Taehyung ^b,d   Fung, Scott K ^a,d   Wong, David K H ^d,e   Mcgilvray, Ian ^a,d   Fischer, Sandra E ^a,d   Allard, Johane P ^a,d  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF GUELPH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ARACHIDONIC ACID; C PEPTIDE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INSULIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CALORIC INTAKE; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DETOXIFICATION; DISEASE SEVERITY; ENDOCRINE FUNCTION TEST; FATTY ACID METABOLISM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE ONTOLOGY; HUMAN; INSULIN BLOOD LEVEL; LIPID METABOLISM; LIPOGENESIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM;

ADULT; CROSS-SECTIONAL STUDIES; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84924772254     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27695     Document Type: Article

References (43)

1. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. Q J Med 2010; 103: 71-83.
2. Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 2013; (28 Suppl. 1): 68-76.
3. LaBrecque D, Abbas Z, Anania F, Ferenci P, Ghafoor Khan A, Goh K-L, et al. World Gastroenterology Organisation Global Guidelines. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Milwaukee, WI: World Gastroenterology Organisation; 2012.
4. Younossi ZM, Gorreta F, Ong JP, Schlauch K, Giacco LD, Elariny H, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int 2005; 25: 760-771.
5. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42: 665-674.
6. Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2011; 39: 1954-1960.
7. Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One 2010; 5: e9570.
8. Zhang Y, Baker SS, Baker RD, Zhu R, Zhu L. Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. PLoS One 2012; 7: e51131.
9. Moylan CA, Pang H, Dellinger A, Suzuki A, Garrett ME, Guy CD, et al. Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 2014; 59: 471-482.
10. Yoneda M, Endo H, Mawatari H, Nozaki Y, Fujita K, Akiyama T, et al. Gene expression profiling of non-alcoholic steatohepatitis using gene set enrichment analysis. Hepatol Res 2008; 38: 1204-1212.
11. Starmann J, Falth M, Spindelbock W, Lanz KL, Lackner C, Zatloukal K, et al. Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One 2012; 7: e46584.
12. Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr 2013; 33: 231-248.
13. Rudkowska I, Paradis AM, Thifault E, Julien P, Tchernof A, Couture P, et al. Transcriptomic and metabolomic signatures of an n-3 polyunsaturated fatty acids supplementation in a normolipidemic/normocholesterolemic Caucasian population. J Nutr Biochem 2013; 24: 54-61.
14. Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, et al. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol 2008; 48: 300-307.
15. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004; 106: 635-643.
16. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-1090.
17. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47: 711-717.
18. Da Silva HE, Arendt BM, Noureldin SA, Therapondos G, Guindi M, Allard JP. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet 2014; 114: 1181-1194.
19. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944-951.
20. Lopez-Vicario C, Gonzalez-Periz A, Rius B, Moran-Salvador E, Garcia-Alonso V, Lozano JJ, et al. Molecular interplay between delta5/delta6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis. Gut 2014; 63: 344-355.
21. Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 2009; 1792: 1080-1086.
22. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
24. Pruitt K, Brown G, Tatusova T, Maglott D. The Reference Sequence (RefSeq) Project. The NCBI handbook [Internet]. Bethesda, MD: National Library of Medicine, National Center for Biotechnology Information; 2002.
25. Du P, Kibbe WA, Lin SM. Lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547-1548.
26. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc 2009; 4: 44-57.
27. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
28. Lau DT, Luxon BA, Xiao SY, Beard MR, Lemon SM. Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. Hepatology 2005; 42: 273-281.
29. Yauk CL, Berndt ML, Williams A, Douglas GR. Comprehensive comparison of six microarray technologies. Nucleic Acids Res 2004; 32: e124.
30. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
31. Ma DW, Ngo V, Huot PS, Kang JX. N-3 polyunsaturated fatty acids endogenously synthesized in fat-1 mice are enriched in the mammary gland. Lipids 2006; 41: 35-39.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
33. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-544.
34. Asselah T, Bieche I, Laurendeau I, Martinot-Peignoux M, Paradis V, Vidaud D, et al. Significant gene expression differences in histologically "normal" liver biopsies: implications for control tissue. Hepatology 2008; 48: 953-962.
35. Liu J, Wen G, Cao D. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives. Recent Pat Anticancer Drug Discov 2009; 4: 246-253.
36. Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997; 38: 2012-2022.
37. Lattka E, Eggers S, Moeller G, Heim K, Weber M, Mehta D, et al. A common FADS2 promoter polymorphism increases promoter activity and facilitates binding of transcription factor ELK1. J Lipid Res 2010; 51: 182-191.
38. Merino DM, Johnston H, Clarke S, Roke K, Nielsen D, Badawi A, et al. Polymorphisms in FADS1 and FADS2 alter desaturase activity in young Caucasian and Asian adults. Mol Genet Metab 2011; 103: 171-178.
39. Peter A, Kovarova M, Nadalin S, Cermak T, Konigsrainer A, Machicao F, et al. PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans. Diabetologia 2014; 57: 2103-2107.
40. Santoro N, Savoye M, Kim G, Marotto K, Shaw MM, Pierpont B, et al. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. PLoS One 2012; 7: e37827.
41. Stojkovic IA, Ericson U, Rukh G, Riddestrale M, Romeo S, Orho-Melander M. The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels. Genes Nutr 2014; 9: 388.
42. Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 2014; 147: 377-384.
43. Zuckerman NS, Noam Y, Goldsmith AJ, Lee PP. A self-directed method for cell-type identification and separation of gene expression microarrays. PLoS Comput Biol 2013; 9: e1003189.